and follow-up echocardiography showed the severity degree of stenosis could be gradually recovered, while a few progressive. Three cases of thirteen fetuses were pulmonary stenosis were with intracardiac malformation and had unfavourable prognosis. The remaining three of sixteen cases were with normal pulmonary confirmed by echocardiography after delivery although they were diagnosed with mild pulmonary stenosis.
Objectives:
To establish the abnormal midline position of descending aorta in four chamber view as a marker for the diagnosis of right-sided aortic arch (RAA). Methods: Detailed fetal echocardiography was performed in 30 cases of right-sided aortic arch. In all the cases emphasis was given on the position of descending aorta, which is normally left paramedian and anterior to fetal spine in four chamber view. Results: Out of 100 patients who were subjected to detailed 2D, 3D ultrasonography and colour Doppler fetal echocardiography for cardiac and extracardiac anomalies, 30 patients who were diagnosed to be a case of right-sided aortic arch, position of descending aorta was studied in relation to fetal spine. The normal position of descending aorta is anterior and left paramedian to the fetal spine. In our study in all the cases the descending aorta was more centrally located anterior to spine in four chamber view. The diagnosis was further supported by the classical three vessel trachea view where the aorta has a course to the right side of trachea (instead to the left). Conclusions: With our study it was concluded that the abnormal midline position of descending aorta can be established as a marker for the diagnosis of right-sided aortic arch in four chamber view even in the hands of less experienced operator.
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In utero treatment of a large symptomatic rhabdomyoma with sirolimus C. Vachon Marceau 3,2 , S. Lee 1,2 , V. Guerra 4 , E. Jaeggi 4 , V. Rhabdomyomas are the most common fetal cardiac tumours, often associated with tuberous sclerosis. They are generally detected in the second or third trimester of pregnancy and grow under the influence of maternal hormones. Although most decrease in size after birth, large lesions (>2cm) can cause ventricular dysfunction, arrhythmia, outflow tract obstruction, fetal hydrops and death. Neonatal treatment for symptomatic rhabdomyomas previously described, include surgical debulking, stenting, anti-arrhythmic therapy and mammalian target of rapamycin (mTOR) inhibition. We document the antenatal use of sirolimus for the treatment of a large fetal rhabdomyoma causing ventricular dysfunction and pericardial effusion at 31 weeks of gestation.
Transplacental treatment with sirolimus was initiated at 31.6 weeks of gestation. An oral loading dose of 15 mg was administered to the mother, followed by 5-8 mg daily, aiming for maternal serum trough levels of 10-15 ng/mL. Within 2 weeks of treatment, the lesion halved in volume with concomitant improvement in ventricular function and a resolution of the tricuspid regurgitation. Sirolimus was stopped 3 weeks prior to delivery to allow for recovery of the maternal immune system. Rebound growth of the rhabdomyoma was observed 2 weeks after stopping the medication. The mother went into spontaneous labour at 39 weeks and delivered a hemodynamically stable neonate who had an uneventful cardiac course.
This case suggests sirolimus as a therapeutic option for high-risk fetal cardiac rhabdomyomas. However, given the limited safety data and potential maternal risks, this option should be reserved for cases with a poor prognosis only.
Supporting information can be found in the online version of this abstract 
